Aurobindo Pharma Limited has published a comprehensive public announcement detailing its ₹800.00 crore share buyback program, providing extensive regulatory disclosures and implementation procedures for shareholders. The pharmaceutical company's board approved this significant capital return initiative on April 6, 2026, with the public announcement published on April 8, 2026.

Buyback Structure and Implementation Details

The company will repurchase up to 54,23,728 equity shares at ₹1,475 per share through the tender offer route using BSE's stock exchange mechanism. The buyback represents 0.93% of total outstanding shares and will be implemented on a proportionate basis with special provisions for small shareholders.

Regulatory Compliance and Financial Framework

The buyback amount represents 3.93% and 2.62% of aggregate paid-up equity capital and free reserves based on standalone and consolidated financial statements as of March 31, 2025, respectively. This remains well within the statutory 10% limit under Companies Act and SEBI regulations.

Premium Structure and Market Positioning

The ₹1,475 buyback price offers attractive premiums across different timeframes:

Promoter Participation and Shareholder Benefits

Promoter and promoter group members, holding 51.82% of total shares, have confirmed their intention to participate in the buyback. The company will reserve 15% of buyback quantum for small shareholders as defined under SEBI regulations, ensuring broader participation benefits.

Implementation Process and Professional Services

The buyback will utilize BSE's acquisition window mechanism with comprehensive professional support:

Funding and Strategic Objectives

The company will fund the buyback through free reserves and permissible sources, excluding borrowed funds. Management outlined three primary strategic objectives: rewarding shareholders with enhanced returns, improving key financial ratios including earnings per share, and benefiting small shareholders through reserved allocation.

Regulatory Documentation and Compliance

The detailed public announcement includes comprehensive statutory auditor reports, permissible capital payment calculations, and extensive regulatory confirmations. The company has obtained necessary lender consents and confirmed compliance with all applicable regulations including Companies Act 2013 and SEBI Buyback Regulations 2018.

Aurobindo Pharma Limited has secured a significant regulatory milestone with the US Food & Drug Administration (USFDA) granting final approval for its Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval positions the company to enter a substantial diabetes medication market as a generic equivalent to AstraZeneca's Farxiga with competitive advantages.

Product Specifications and Market Position

The approved Dapagliflozin Tablets are bioequivalent and therapeutically equivalent to the reference listed drug Farxiga Tablets, manufactured by AstraZeneca AB. The products will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the company, with immediate market launch planned.

Market Exclusivity and Competitive Advantage

Aurobindo Pharma has secured a notable competitive position by being among the first ANDA applicants to submit a substantially complete application with paragraph IV certification for Dapagliflozin Tablets. This early filing grants the company eligibility for 180 days of shared generic drug exclusivity, providing a significant market advantage during the initial launch period.

The approved product addresses a substantial market opportunity, with IQVIA MAT data indicating an estimated market size of US$ 10.2 billion for the diabetes treatment segment.

Regulatory Portfolio Expansion

With this latest approval, Aurobindo Pharma's USFDA portfolio has expanded to 579 total ANDA approvals. The portfolio breakdown includes:

Therapeutic Application

Dapagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. This therapeutic application addresses a significant healthcare need in the growing diabetes treatment market.

Company Overview

Aurobindo Pharma Limited operates as an integrated global pharmaceutical company headquartered in Hyderabad, India. The company maintains an extensive manufacturing network with over 30 manufacturing and packaging facilities approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company's operations span over 150 countries globally, with a robust product portfolio covering seven major therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic medications.